Lexicon Pharmaceuticals, Inc.
LXRX
$0.53
-$0.0019-0.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.55M | 1.75M | 1.65M | 1.13M | 702.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.55M | 1.75M | 1.65M | 1.13M | 702.00K |
| Cost of Revenue | 25.93M | 25.85M | 17.81M | 14.40M | 14.83M |
| Gross Profit | 621.00K | -24.10M | -16.16M | -13.27M | -14.13M |
| SG&A Expenses | 21.06M | 39.59M | 39.19M | 32.06M | 31.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.99M | 65.44M | 57.00M | 46.46M | 46.00M |
| Operating Income | -20.44M | -63.69M | -55.35M | -45.33M | -45.30M |
| Income Before Tax | -33.77M | -64.81M | -53.43M | -48.40M | -49.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.77M | -64.81M | -53.43M | -48.40M | -49.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.77M | -64.81M | -53.43M | -48.40M | -49.76M |
| EBIT | -20.44M | -63.69M | -55.35M | -45.33M | -45.30M |
| EBITDA | -20.31M | -63.57M | -55.22M | -45.19M | -45.15M |
| EPS Basic | -0.09 | -0.18 | -0.17 | -0.20 | -0.20 |
| Normalized Basic EPS | -0.04 | -0.11 | -0.11 | -0.12 | -0.12 |
| EPS Diluted | -0.09 | -0.18 | -0.17 | -0.20 | -0.20 |
| Normalized Diluted EPS | -0.04 | -0.11 | -0.11 | -0.12 | -0.12 |
| Average Basic Shares Outstanding | 361.49M | 361.49M | 310.84M | 245.39M | 244.93M |
| Average Diluted Shares Outstanding | 361.49M | 361.49M | 310.84M | 245.39M | 244.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |